Clinical trials: Zoledronic acid, completed
Osteoporosis, Bone Loss
Zoledronic Acid for Osteoporosis in the Elderly
This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious…
- Conditions
- Osteoporosis, Bone Loss, Fragility Fractures
- Trial name
- ZEST (NCT00558012)
- Testing
- Intravenous zoledronic acid, Vitamin D 800 IU/daily, Calcium 1200 mg/daily
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- University of Pittsburgh
Multiple Myeloma, Breast Cancer
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic…
- Trial name
- NCT00424983
- Testing
- Zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Bone Metastases, Breast Cancer
Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation
Zoledronic acid (Zometa) belongs to a class of drugs called bisphosphonates. Bisphosphonates are used in bone metastases to keep the cancerous lesion under control in the bone and to help prevent calcium level elevations in the…
- Conditions
- Bone Metastases, Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00264420
- Testing
- zoledronic acid
- Volunteers
- 4 people
- Sponsor
- The Cleveland Clinic
Postmenopausal Osteoporosis
Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass
The primary aim of the study is the comparative effect of zolendronic acid versus denosumab on serum sclerostin levels in postmenopausal women with low bone mass.
- Trial name
- DenoZol (NCT01572545)
- Testing
- Denosumab, Zoledronic acid
- Where
- 3 sites in Greece
- Volunteers
- 91 people
- Sponsor
- Aristotle University Of Thessaloniki
Postmenopausal Osteoporosis
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
In contrast with bisphosphonates,discontinuation of denosumab results in gradual loss of bone mineral density gains. The investigators aim to evaluate whether in patients treated with denosumab, a single zoledronic acid infusion…
- Trial name
- AfterDmab (NCT02499237)
- Testing
- Denosumab, Zoledronic acid
- Where
- 2 sites in Greece
- Volunteers
- 57 people
- Sponsor
- 424 General Military Hospital
Osteopenia
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
- Trial name
- NCT00132808
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 581 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer, Metastatic Cancer
Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00588913
- Testing
- aldesleukin, therapeutic autologous lymphocytes, zoledronic acid
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Tokyo Women's Medical University
Metastatic Breast Cancer, Bone Metastases
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1 mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth factor (VEGF) levels in breast cancer patients…
- Trial name
- NCT00524849
- Testing
- Zoledronic acid
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Neuroblastoma
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00885326
- Testing
- Bevacizumab, cyclophosphamide, zoledronic acid
- Where
- 15 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Hip Fractures, Osteoporosis
Zoledronate Early to Hip Fracture Patients - Safe and Effective?
To prevent hip fracture patients for having another fracture, secondary fracture preventing medication should be given as soon as possible.
- Trial name
- ZEBRA (NCT05025293)
- Testing
- Zoledronic Acid 5Mg/Bag 100Ml Inj, sodium chloride
- Where
- Norway
- Volunteers
- 228 people
- Sponsor
- Lene Bergendal Solberg
Prostate Cancer
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
The present study will give information about the course over time in skeletal-related events (SRE) in prostate cancer patients with bone metastases treated with zoledronic acid 4 mg administered as a 15-minute infusion every 4…
- Trial name
- NCT00219219
- Testing
- Zoledronic acid
- Where
- Italy
- Sponsor
- Novartis
Bone Fragile, Bisphosphonate-Associated Osteonecrosis
Efficacy and Safety on the Use of Bisphosphonates in Paediatrics
The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.
- Conditions
- Bone Fragile, Bisphosphonate-Associated Osteonecrosis, Children, Adverse Events
- Trial name
- Bisphosphonate (NCT04012320)
- Testing
- No intervention, observational study
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Prostate Adenocarcinoma
ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma
This study will determine the delayed neurotoxicity (12 months) of a hypofractionated high dose irradiation (3 Gy x 9) associated with zoledronic acid.
- Trial name
- GEMO (NCT01219790)
- Testing
- external radiotherapy, Acide zoledronic
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Institut Cancerologie de l'Ouest
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00039104
- Testing
- rebimastat, zoledronic acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment
- Trial name
- NCT00242567
- Testing
- Zoledronic Acid, Androgen Deprivation Therapy (ADT)
- Where
- 27 sites in Australia, Brazil and 8 more
- Volunteers
- 522 people
- Sponsor
- Novartis Pharmaceuticals
Bone Neoplasms
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events…
- Trial name
- NCT00434447
- Testing
- Zoledronic acid
- Where
- 10 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study
The aim of this study is to acquire preliminary, pilot data over a 2-year period on the safety and efficacy of subcutaneous denosumab versus the current CHEO standard-of-care (intravenous zoledronic acid) for the treatment of…
- Trial name
- NCT02632916
- Testing
- Zoledronic Acid, Denosumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Eastern Ontario
Charcot Arthropathy, Diabetes Complications
Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus
Charcot neuropathic osteoarthropathy (CNO) is a progressively destructive process resulting from significant peripheral neuropathy of almost any aetiology. Diabetes mellitus has emerged as the commonest cause of CNO.
- Trial name
- NCT03289338
- Testing
- Zoledronic Acid, Methylprednisolone
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Prostate Cancer
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
An open, multicenter and prospective study to evaluate the impact of the treatment with zoledronic acid 4 mg, on the quality of life and the skeletal-related events in patients with prostate cancer and bone metastasis that…
- Trial name
- NCT00237146
- Testing
- Zoledronic acid
- Where
- Venezuela
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals